-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Benzinga·09/24/2026 13:07:02
Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.